PPARα/γ agonist 5

• Description :

  PPARα/γ agonist 5 is a dual PPARα/γ agonist with significant biological activity exhibited at low concentrations. The EC50 of PPARα/γ agonist 5 are 0.358μM and 1.21μM respectively, showing its potential in inhibiting type 2 diabetes and lipid metabolism disorders. PPARα/γ agonist 5 was selected for clinical development due to its high efficacy[1].

• UNSPSC :

  12352005

• Target :

  PPAR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/pparα-γ-agonist-5.html

• Smiles :

  OC([C@H](OC)CC1=C2C(C=CS2)=C(C=C1)OCCC3=C(C)OC(C4=CC=CC=C4)=N3)=O

• Molecular Formula :

  C24H23NO5S

• Molecular Weight :

  437.51

• References & Citations :

  [1]Aleglitazar, a new, potent, and balanced dual PPARa/c agonist for the treatment of type II diabetes

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [849150-59-0]